Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib sequential chemotherapy in advanced non-small cell lung cancer
ChiCTR1900024189Phase 4Recruiting
- Sponsor
- Shanxi Provincial Hospital of Traditional Chinese Medicine
- Start
- Mar 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib and docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanxi Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Progression-free survival. Started Mar 2017; status: recruiting.
02
Drugs
Rivoceranibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900024189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024189.